Roquefort Therapeutics' portfolio consists of five novel patent-protected pre-clinical anti-cancer medicines
The highly complementary profile of five best-in-class medicines consists of:-
- Midkine antibodies with significant in vivo efficacy and toxicology studies;
- Midkine oligonucleotide therapeutics with novel anti-cancer gene editing action;
- Midkine mRNA therapeutics targeting solid tumours;
- STAT-6 siRNA therapeutics targeting solid tumours with significant in vivo efficacy; and
- MK cell therapy with direct and NK-mediated anti-cancer action.
![3D protein enzyme clusters illustration lilac in colour on blue green background](/sites/default/files/inline-images/Portfolio-1.jpg)
![Roquefort Therapeutic PLC Logo](/sites/default/files/inline-images/icon-bg.png)